Dr. Reddy’s Launches Generic Olopatadine in U.S. Market

Dr. Reddy’s Laboratories Ltd. has announced the launch of its over-the-counter (OTC) Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7%, in the U.S. market. This product is the generic equivalent of Extra-Strength Pataday® Once Daily Relief and has been approved by the U.S. Food and Drug Administration (USFDA). The launch marks Dr. Reddy’s entry as the first-to-market for this specific generic formulation.

The Pataday® brand, which Dr. Reddy’s new product is equivalent to, had U.S. sales of approximately $70 million for the 52-week period ending December 27, 2025, according to NIQ data. This financial figure highlights the market potential for Dr. Reddy’s new product in the competitive U.S. OTC eye-care market. The company has not disclosed specific financial terms related to the launch of this product.

The Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7%, is an antihistamine eye drop indicated for the temporary relief of itchy eyes caused by allergens such as pollen, ragweed, grass, animal hair, and dander. The product is available in a 2.5 mL bottle, expanding Dr. Reddy’s existing portfolio in the OTC eye-care segment, which already includes Olopatadine Hydrochloride Ophthalmic Solution in 0.2% and 0.1% strengths.

Dr. Reddy’s Laboratories has positioned this launch within the context of its broader strategy to provide store-brand equivalents of OTC brands in the U.S. market. The company emphasizes its capabilities in delivering these products to retail customers, thereby enhancing its collaboration with them. This launch is part of Dr. Reddy’s ongoing efforts to expand its presence in the U.S. pharmaceutical market, particularly in the OTC segment.

The launch of the Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7%, follows its approval by the USFDA, although specific dates for market availability were not disclosed in the filing. The product is expected to be distributed through Dr. Reddy’s established channels in the U.S. market.

Dr. Reddy’s Laboratories Ltd. is a global pharmaceutical company headquartered in Hyderabad, India. Established in 1984, the company focuses on providing access to affordable and innovative medicines. Its product portfolio includes APIs, generics, branded generics, biosimilars, and OTC products. Dr. Reddy’s major markets include the USA, India, Russia & CIS countries, China, Brazil, and Europe. The company is committed to sustainability and ESG goals, aiming to set high standards in environmental stewardship and governance.